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Transmembrane signals initiated by a range of extracellular
stimuli converge onmembers of theGq family of heterotrimeric
G proteins, which relay these signals in target cells. Gq family G
proteins comprise Gq, G11, G14, and G16, which upon activa-
tion mediate their cellular effects via inositol lipid–dependent
and –independent signaling to control fundamental processes
in mammalian physiology. To date, highly specific inhibition of
Gq/11/14 signaling can be achieved only with FR900359 (FR)
and YM-254890 (YM), two naturally occurring cyclic depsipep-
tides. To further development of FR or YMmimics for other G
subunits,wehere set out to rationally designG16proteinswith
artificial FR/YM sensitivity by introducing an engineered depsi-
peptide-binding site. Thereby we permit control of G16 func-
tion through ligands that are inactive on theWT protein. Using
CRISPR/Cas9-generated Gq/G11-null cells and loss- and
gain-of-function mutagenesis along with label-free whole-cell
biosensing, we determined the molecular coordinates for
FR/YM inhibition of Gq and transplanted these to FR/YM-in-
sensitive G16. Intriguingly, despite having close structural sim-
ilarity, FR and YM yielded biologically distinct activities: it was
moredifficult toperturbGq inhibitionbyFRandeasier to install
FR inhibition onto G16 than perturb or install inhibition with
YM. A unique hydrophobic network utilized by FR accounted
for these unexpected discrepancies. Our results suggest that
non-Gq/11/14 proteins should be amenable to inhibition by FR
scaffold–based inhibitors, provided that these inhibitors mimic
the interaction of FR with G proteins harboring engineered
FR-binding sites.
GTP/GDP exchange and the intrinsic GTPase activity of
GTP-binding proteins constitute widespread regulatory mech-
anisms in cells. These are utilized by heterotrimeric  G
proteins, downstream effectors of G protein–coupled recep-
tors (GPCRs),6 to directly or indirectly regulate numerous
physiological processes in mammals (1–4). G proteins are
grouped into fourmajor families (Gs, Gi/o, Gq/11, andG12/13)
on the basis of subunit homology and function (3, 5–7). Com-
mon to all G proteins is a highly conserved molecular architec-
ture and the mechanism they use to allow cells to respond to
extracellular cues (8–12).
Previous X-ray crystallographic analysis revealed that G pro-
teins from different organisms and subclasses share nearly
identical structural features (9–16). They are composed of two
domains, a GTPase “Ras-like” domain that is conserved in all
members of the GTPase superfamily and is homologous to the
monomeric GTPase Ras and an all--helical domain that is
unique to heterotrimeric G proteins (17, 18). Both domains are
held together by two flexible linkers and tightly sandwich the
guanine nucleotide (19, 20). Separation of Ras and the helical
domain to facilitate GDP/GTP exchange and thereby initiate
cellular signaling may occur spontaneously (21–24) or in
response to internal structural rearrangement triggered by acti-
vated GPCRs that act as guanine nucleotide exchange factors
(4, 25–27). At steady state, signaling output is balanced by the
competing actions of GPCRs, which accelerate GTP binding,
and GTPase-activating proteins, which accelerate GTP hydro-
lysis (28). In this way, G proteins function as nucleotide state–
dependent molecular switches that are critical to defining the
duration of G protein signaling.
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Although this form of signal transduction is basic to the
mechanisms that cells have evolved for responding to hor-
mones, neurotransmitters, and a variety of other ligands,
pharmacological control of G protein function is by far more
difficult to achieve (29, 30). Indeed, despite discovery of hetero-
trimeric G proteins about 30 years ago, very few pharmacolog-
ical agents allow precision control of the G protein cycle.
Among these are the two bacterial toxins, pertussis toxin and
cholera toxin, which act via covalent modification of the G
subunits Gi and Gs to ablate Gi and mask Gs coupling,
respectively (31, 32). However, noncovalent control of G pro-
tein function in a subfamily-specific manner has so far only
been accomplished for Gq family proteins. One such notable
Gq-inhibiting agent is FR900359 (FR; see Fig. 1A), a plant-de-
rived cyclic depsipeptide with exceptional selectivity for Gq,
G11, and G14 over all other G proteins. Mechanistically, FR
interdicts Gq activity via inhibition of GDP release and was
therefore classified by us as a guanine nucleotide dissociation
inhibitor (33). Because FR is active in intact cells (33–37), on the
level of isolated organs (33, 38, 39), and in the living organism
(36, 38, 40), it has been used widely to probe the biological
consequences that arise from specific inhibition ofGq signaling
cascades in vitro and in vivo (33, 36, 38). How FR achieves this
specific inhibition at the molecular level is presently unknown.
Therefore, the first goal of our study was to map the site of FR
actionwithinGq bymutational analysis. This was guided by and
basedon the cocrystal structure ofYM-254890 (YM; seeFig. 1B), a
structurally closely related Gq inhibitor, in complex with a Gi/q
chimeric protein, which previously provided a framework for
understanding YM’s action in great molecular detail (19). Unex-
pectedly, we found that FR is distinct from YM in that shared but
divergent amino acid networks within a common binding site
account for its biological effects.Nevertheless, this common site is
of interest for two reasons: it is sufficiently conserved to imply that
other G subunits may be inhibited by similar mechanisms but
sufficiently diverse to posit that FR or YM analogs may be devel-
oped with altered G specificity profiles. However, to date and
despite intense efforts (41–47), no single FRorYManalog inhibits
G proteins apart from Gq, G11, and G14 (41, 44, 46–48), raising
the possibility that rational design of suchmoleculesmay bemore
challenging than generally anticipated (1, 19, 33, 45).
Therefore, rather than engineering additional novel analogs,
our second goal was to engineer novel G proteins with artifi-
cial sensitivity toward FR and YM. In the study described
herein, we chose G16, which is not naturally regulated by FR,
for reconstruction of functional inhibitor sites. Although the
ultimate goal of our proof-of-concept study is to facilitate dis-
covery of FR scaffold–based inhibitors with altered G speci-
ficities,Gproteinswith engineered depsipeptide-binding sites
may be considered a first step along this path to support ratio-
nal design of such molecules.
Results
Differential inhibition of Gq family proteins by FR and YM
In-depth insight into inhibitor topology on WT Gq is a
prerequisite for reconstruction of functional FR/YM sites
into G proteins that are naturally not inhibitor-regulated.
Although select interaction points between YM and Gq have
been identified previously by cocrystal andmutational analyses
(19), it is elusive at present whether Gq proteins can be
designed that maintain catalytic function but are mutationally
resistant to the inhibitor. Because FR and YM inhibit Gq, G11,
and G14 but not G16, the closest FR-insensitive relative, we
reasoned that a catalytically active depsipeptide-resistant Gq
should result from switching the relevant Gq residues to their
counterpart sequences in G16 provided that G16 is inert to
both inhibitors. Therefore, we investigated a possible direct
inhibition by FR and YM of G16 using real-time live-cell phe-
notypic biosensor assays based on dynamicmass redistribution
(DMR) in CRISPR/Cas9 genome-edited HEK293 cells deficient
in Gq and G11 (hereafter “Gq/G11-null” cells). This cel-
lular background allows analysis of Gq family proteins without
the confounding variable of endogenously expressed Gq and
G11. As expected, Gq/G11-null cells were unresponsive to
carbachol (CCh), which activates Gq-sensitive endogenous
muscarinic M3 receptors (Fig. S1), but displayed robust and
concentration-dependent activity profiles upon re-expression
of WT Gq or G16 (Fig. 1C). In agreement with its reported
selectivity profile, YM potently inhibited Gq but was com-
pletely inactive at G16 (Fig. 1D). FR, in contrast, blunted Gq
activation with potency equivalent to that of YM and, addition-
ally, G16 at the highest applied concentrations (Fig. 1E). Inhi-
bition of cell function at high FR concentrations did not result
from off-target activity but was specific to G16 because FR (i)
did not produce anyDMRwhen applied alone (Fig. S2A) and (ii)
did not diminish signals evoked with epidermal growth factor
as a non-Gq stimulus (Fig. S2B). Thus, despite their structural
similarity, FR is distinct from YM in that it does display some
residual interaction with G16, a feature that is also recapitu-
lated in the more traditional inositol monophosphate (IP1)
accumulation assay (Fig. S3) and that may impact gain- and
loss-of-function mutagenesis.
Key interaction points for YM inhibition of Gq affect FR to a
lesser extent
We next explored key sites for FR inhibition of Gq by tar-
geted mutagenesis. To this end, we initially replaced Gq resi-
dues previously reported to engage in direct interactions with
YM by the matching G16 counterparts: V184M, I190N, and
P193C (19). In fact, of all 17 amino acids with side chains within
5 Å of YM, these three are completely conserved only in YM-
sensitive Gq/11/14, suggesting that they act as key specificity
determinants (Fig. 2,A andB). They line the linker 2 region, also
known as Switch I, which together with linker 1 provides the
interdomain cleft for occupancy by YM to stabilize Gq in its
GDP-bound form (Fig. 2, C andD). We predicted FR to engage
Gq the same way as YM, and as anticipated, modeled FR reca-
pitulated this interaction (Fig. 2E). Unexpectedly, Gq inhibition
assays showed that FR sensitivity of all three mutants was
hardly affected (Fig. 2F). However, when single mutants were
combined to double and triple mutants, FR sensitivity was
markedly reduced by almost 2 orders of magnitude (Fig. 2G).
These data corroborate the notion that linker 2/Switch I also
ensures specificity of FR action but is not sufficient to explain
selectivity entirely. A similar picture emerged frommutational
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analysis of YMwith the only difference being that activity loss of
YM was always greater than that of FR for individual mutants
(Fig. 2, H and I).
Shared and divergent amino acid networks explain
differential inhibition of Gq familymembers by FR and YM
Because none of our mutant proteins were inhibitor-resist-
ant, we searched for additional residues that, when mutated,
may incur activity loss for the two depsipeptides. We focused
our attention on residues that (i) differed between Gq and
G16, (ii) were not addressed previously by mutagenesis, and
(iii) were located on both linkers, including adjacent regions, to
either directly interact with the depsipeptides (if side-chain or
G atomswerewithin 5Å toYM) or to be close enough to assist
in stabilizing the inhibitor–protein interactions. Aspartate 71
(Asp-71) and valine 182 (Val-182) fulfilled these criteria (Fig.
3A; see also Fig. 2A): Asp-71 is part of an aspartic acid–arginine
salt bridge that likely provides the interface between the depsi-
peptides and linker 1 by stabilizing and maintaining the
inhibitor–linker 1 spacing (Fig. 3B). Because accurate place-
ment of salt-bridging residues in proteins is crucial for intra-
and intermolecular recognition (49–51), we reasoned that
exchange of aspartate for glutamic acid, the matching G16
counterpart, may impact inhibitor sensitivity in a negative way.
Likewise, replacement of the hydrophobic valine by the corre-
sponding polar serine (V182S) may destabilize a hydrophobic
network (Phe-75, Leu-78, Val-182, Val-184, and Ile-190) that is
essential for YM and likely also for FR (Fig. 3C). Gq inhibition
assays showed that individual substitutions were without effect
on inhibitor function (Fig. 3, D and E), whereas combined
replacement of eitherD71E orV182Swithin theV184M/I190N
doublemutant context essentially abolished YM sensitivity and
severely compromised that of FR (Fig. 3, F andG). Replacement
of all five diverging residues (GqFIVE) was required and suffi-
cient to attenuate FR action to the same extent as observed on
WT G16. In fact, GqFIVE recapitulated the pharmacological
profiles observed for FR and YM on native G16 in both DMR
(compare Fig. 3,H and I, with Fig. 1,D and E) and IP1 accumu-
Figure 1. FR andYMdifferentially inhibit signalingofGq familymembersGqandG16.Chemical structures of FR (A) and YM (B) with differingmoieties
highlighted in yellow and blue, respectively. C, concentration-dependent activation profiles of CCh in HEK293 Gq/G11-null cells transfected to express WT
Gq or G16 using label-free DMR biosensing. Ci, concentration-effect curves of the traces depicted in C. D and E, concentration-dependent inhibition of cell
responses induced with CCh at its EC80 by YM (D) and FR (E) in cells expressing Gq or G16. Di and Ei, concentration-inhibition relationships for the traces
shown in D and E. DMR recordings are representative (mean S.E.) of at least four independent biological replicates conducted in triplicate (C–E), whereas
concentration-effect relationships are means S.E. from at least four independent biological replicates. pm, wavelength shift in picometer.
Transfer of FR900359 and YM-254890 sites fromGq to G16
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lation assays (Fig. S4). For all Gq loss-of-function mutants,
potency measures for activation by CCh were similar to that of
Gq WT (Fig. S5 and Table S1) with signaling amplitudes well
correlated to cellular abundance (Fig. S6).
Together, our loss-of-function mutagenesis revealed two
recurring themes: (i) inhibitors were largely unaffected by sin-
gle pointmutations (at best 7-fold forYMat I190N), and (ii) YM
was less tolerant to substitutions as compared with FR, i.e.
became inactive by fewer changes (Fig. 3J and Table S1). From
these data, we concluded that a network of hydrophobic inter-
actions rather than individual anchor points is essential for
tightening the ligands to their target site. FR, which is more
hydrophobic than YM (Figs. 1, A and B, and 3C), is more toler-
ant to loss of hydrophobic interactions and may, therefore, be
more difficult to detach.
Quantitative reconstruction of functional FR and YM sites
within G16
Based on our loss-of-function mutagenesis, transplantation
of an entire hydrophobic network including multiple interac-
tions rather than individual amino acid replacements is likely
required to install FR and YM sensitivity onto G16. Indeed,
Figure 2. Key interaction points for YM inhibition of Gq affect FR to a lesser extent. A, amino acid sequence alignments and secondary structure features
of Gq family  subunits. Secondary structure assignments (-helices, -strands, and linker regions) and ruler numbering are derived from Gi/q (PDB code
3AH8). Conserved residues aremarkedwith asterisks. Gq residues implicated both directly and indirectly in YM interaction are highlighted in light blue. G16
residues that differ from Gq in either direct YM-binding regions or adjacent areas are color-coded ochre. B, interaction surface of YM on the Gq tertiary
structure including Asp-71; the color code of the sequence alignment is kept to visualize direct YM–Gq contacts (light blue) and sequence deviations from
G16 at equivalent locations (ochre). C, surface representation of YM-bound Gi/q tertiary structure (PDB code 3AH8) composed of the GTPase and helical
domain that are connected by linker 1 (L1) and linker 2 (L2;switch I), respectively. D and E, features of YM (D) and FR (E) interaction with Gq as overall and
close-up views. Residues previously defined as important for YM–Gq interaction are shown as sticks and colored beige. FRwasmodeled into theGq-binding
site assuming equivalent anchor points as comparedwith YM; GDP is shown as spheres. F–I, inhibition by FR (F andG) and YM (H and I) of G protein–dependent
whole-cell activation profiles in CRISPR/Cas9 Gq/G11-null cells transfected to express the indicated Gq single (F and H) and double and triple (G and I)
mutants. G proteins were activated via endogenous M3 receptors upon challenge with CCh at its EC80. Shown are representative whole-cell recordings along
with concentration-inhibition curves for each individual mutant (Fi–Ii). -Fold shifts above the curves denote the loss of inhibitor potency for selectedmutants
versus WT Gq. All DMR traces depict means of three technical replicates. Concentration-inhibition curves are means S.E. from at least three independent
biological replicates. pm, wavelength shift in picometer.
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exchange of each of the five diverging amino acids by the
matching Gq counterparts had little to no effect on G16 inhi-
bition by YM (Fig. 4A). Inhibition by FR, in contrast, was mea-
surably improved by each individual substitution (Fig. 4B). We
then gradually built up the inhibitor–Gq interface using dou-
ble (Fig. 5, A and B), triple (Fig. 5, C and D), and quintuple
mutants (Fig. 5, E and F; see Figs. S7 and S8 for validation of
function and expression of G16 mutants). Of these, G16FIVE,
the quintuple mutant with combined replacement of all diver-
gent residues, conferred the largest degree of G16 inhibition for
FR and YM in both DMR (Fig. 5, E and F) and IP1 accumulation
assays (Fig. S9). Although depsipeptide pharmacology on
G16FIVE was almost superimposable with that on Gq WT
(compare Fig. 5, E and F, with Fig. 1, D and E), inhibition of
G16 by FR was more readily introduced than by YM (Fig. 5G
and Table S2).
Unique hydrophobic interactions account for the divergent
pharmacological profiles of FR and YM
We reasoned that extent and magnitude of hydrophobic
interactions may account for this phenomenon and that FR
may be superior in harnessing the benefit of such interactions.
Figure 3. Fewer amino acid changes are required to achievemutational resistance of Gq to YM. A, depsipeptide-binding site of YM- and FR-bound Gq.
Residues directly interacting with YM and FR (Val-184, Ile-190, and Pro-193) or involved in precise positioning of inhibitors at their target site (Asp-71 and
Val-182) are shown in sticks and colored beige; GDP is shown as spheres. B, zoomed-in view into the Gq Asp-71–Arg-60 salt bridge (yellow stippled line,
Glu-74–Arg-63 in G16) that stabilizes YM– and FR–linker 1 interaction. Note that Asp-71 does not form specific contacts to YMand FR. C, zoomed-in view into
hydrophobic interactions (green stippled lines) formed between YM or FR and the hydrophobic cluster in the Gq interdomain cleft with relevant residues
named and/or shown as sticks in beige. Note that FR producesmore hydrophobic interactions as comparedwith YM.D–I, DMR analysis of Gq loss-of-function
mutants in CRISPR/Cas9 Gq/G11-null cells transfected to express the indicated constructs. Data show concentration-dependent inhibition of G protein–
mediated whole-cell activation profiles by YM (blue) and FR (orange) in cells harboring single (D and E), triple (F and G), and quintuple Gq mutants (H and I).
Shown are representative traces (D–I; mean  S.E. of technical triplicates) and concentration-inhibition relations that are means  S.E. from at least three
independent biological replicates (Di–Ii). -Fold shifts above selected curves indicate loss of inhibitor sensitivity for individual mutants versus WT Gq. pm,
wavelength shift in picometer. J, pharmacological profiles of G protein inhibition that distinguish FR fromYM. Plotted are the inhibitory potencies (pIC50) of FR
and YM for all Gq loss-of-function constructs with Gq and G16WT for comparison. Activity of YM on GqFIVE and G16 is denoted as arbitrarily low (pIC50 3).
This radial multiaxis plot provides a closed polygonal profile for each inhibitor, illustrating that YM becomes inactive with fewer amino acid changes.
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Figure4. Singlegain-of-functionmutantsmeasurably supportG16 inhibitionbyFRbutnotYM.CRISPR/Cas9Gq/G11-null cells ectopically expressing
the indicated G16 gain-of-functionmutants were stimulated with CCh at its EC80 to enable quantification of inhibitory profiles for YM (A) and FR (B). This set
of DMR recordings (technical triplicates) is representative of at least three additional experiments; concentration-inhibition profiles for each mutant are the
means S.E. of at least three independent biological replicates .-Fold increases of FR inhibitory potency are indicated for selected mutants. pm, wavelength
shift in picometer.
Figure 5. Quantitative reconstruction of functional FR and YM sites within G16. A–F, G16 sensitization toward inhibition by YM (blue traces) and FR
(orange traces) is achieved by gradual build-up of inhibitor sites using double (A and B), triple (C and D), and quintuple mutants (E and F). Shown are
representative real-time recordings (A–F; technical triplicates) and corresponding concentration-effect relationships (Ai–Fi; means S.E. from at least three
independent biological replicates) obtained by DMR biosensing in CRISPR/Cas9 cells ectopically expressing the indicated G variants. pm, wavelength shift in
picometer.G, wheel chart summarizing the divergent pharmacological profiles of FR and YM. Plotted are the inhibitory potencies (pIC50) of both inhibitors for
all G16 gain-of-function mutants with Gq and G16WT included as comparators. Lack of detectable YM inhibition is denoted as arbitrarily low activity (pIC50
 3). The closed polygonal profiles indicate that inhibition of G16 by FR was more readily introduced than by YM.
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In line with this prediction, FR inhibition was abolished in
G16 mutants designed to diminish (F78A) or disrupt (F78K)
key hydrophobic contacts between FR and the side chain of
Phe-78, the Phe-75 counterpart and only remnant of the hydro-
phobic tetrad within the G16 interdomain cleft (Fig. 6,A and B;
see Fig. S10 for validation of expression and function of both
mutants). Likewise, only the naturally occurring FR-2 (43) but
not the fully synthetic YM-10 (45) retained inhibition of G16 at
high concentrations (Fig. 6, C and D). Thus, structural modifi-
cations on the ligand and the protein side corroborate the
notion that Phe-78 is crucial for G16 anchorage of FR at high
concentrations and likely also for the ease to install FR inhibi-
tion onto G16 with fewer mutations. More generally, the strik-
ing differences in the extent of hydrophobic interactions
formed between the inhibitors and their protein targets likely
explain the divergent pharmacological profiles of FR and YM
(Fig. 7). Relative toGq,G16 has significantly fewer hydrophobic
residues than what would be needed to accommodate FR or
YM. However, introduction of the hydrophobic cluster is
required and sufficient to convert FR andYM into potent inhib-
itors of this naturally not FR/YM-regulated protein. Therefore,
we anticipate that FR and YM mimics may employ this same
basic mechanism of inhibition to silence function of FR/YM-
insensitive G proteins.
Discussion
FR and YM, two naturally occurring cyclic depsipeptides, are
invaluable pharmacological tools for probing Gq-mediated cel-
lular responses. Because of their specificity, they have become
instrumental in defining and diagnosing the contribution of Gq
proteins to complex biological processes in vitro and ex vivo
(33–39, 52–59). FR and YM share a common mechanism of G
protein inhibition: they act as guanine nucleotide dissociation
inhibitors that preserve GDP-bound heterotrimers in their
inactive state (19, 33). Although there is precedence for this
mechanism of action (60), their site of action is unique. X-ray
crystallographic evidence revealed that YM “dives” into a cleft
between two interdomain linkers that connect the GTPase and
the helical domain of G, which buries the bound nucleotide
(19). Stabilization of these interdomain linkers directly
Figure 6. Hydrophobic Phe-78 buried in the interdomain cleft accounts for inhibition of G16 by FR. A, homology model of FR-bound G16 based on
YM-bound Gi/q (PDB 3AH8) with orange mesh and gray surface representing the vdW (van der Waals) surface of FR and G16, respectively. FR, via its
N-acetyl-hydroxyleucine side chain (the “isopropylmoiety”), engages inhydrophobic interactionswithPhe-78 (green stippled lines) inG16WT. This interaction
cannot take place in F78A, as represented by the significant reduction in surface complementarity, or in F78K, where repulsive forces (red stippled lines)
between Lys-78 and FR likelymake favorable interactions impossible. B, CRISPR/Cas9Gq/G11-null cells transfected to expressG16or the indicatedmutant
isoformswere pretreatedwith FR at the indicated concentrations prior to stimulationwith CCh at its EC80. High concentrations of FR inhibit G16-mediated cell
responses but not those evoked by F78A and F78Kmutants. C, chemical structures of the FR and YM hybrid molecules FR-2 (43) and YM-10 (45). The naturally
occurring FR-2 retains theN-acetyl-hydroxyleucinebuildingblockof FR (yellowmarking) alongwith the ester-linked side chainof YM (N-acetyl-hydroxyleucine;
blue marking). YM-10 contains the N-acetyl-threonine building block of YM (blue marking) but the ester-linked side chain of FR, which is composed of an
N-propionyl-hydroxyleucine (yellowmarking).D, effects of FR-2 and YM-10 on CCh-mediated G16 activation in CRISPR/Cas9 Gq/G11-null cells. Data shown
in B andD are representative real-time recordings (technical triplicates) alongwith concentration-inhibition relations (Bi andDi) that depictmeans S.E. from
three independent biological replicates. If not shown, error bars lie within dimensions of the symbols. pm, wavelength shift in picometer.
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accounts for suppression of GDP release by YM because the
hinge motion that is required for movement of the helical
domain away from the GTPase domain to facilitate nucleotide
exchange and thereby initiate cellular signaling cannot take
place. The mutagenesis results of our study suggest that FR
operates via comparable mechanisms to achieve its specific
blockade of Gq.
Although each G subunit preserves the interdomain cleft,
FR and YM only stabilize Gq, G11, and G14 in their GDP-
bound forms (19, 33). The basis for this remarkable specificity
likely lies in the nature of molecular recognition of YM and FR
by their protein targets: hydrophobic interactions dominate the
interface between the depsipeptides and Gq at this interdo-
main cleft (Fig. 7). YM and evenmore so FR create an extensive
hydrophobic interface that interacts with nonpolar amino acids
of Gq/11/14 (Phe-75, Leu-78, Val-184, and Ile-190; Gq resi-
due numbering), which account for a significant proportion of
nonpolar contacts within the interdomain cleft. Equivalent
interactions between FR or YMand the remainingG subunits,
including G16, cannot be formed because their interdomain
cleft is considerably less hydrophobic (Fig. 7). However, phar-
macological control over G16 by FR scaffolds is achievable pro-
vided all relevant anchoring points are installed to mimic the
interaction between FR and WT Gq. Similarly, a fully func-
tional FR site has recently been engineered into FR-insensitive
Gi (61). This was achieved by swapping a total of eight resi-
dues at a time of Gi for the equivalent Gq amino acids to
enable effective allosteric inhibition of nucleotide exchange by
FR (61). Although only two of the eight mutated residues were
identical in G16FIVE (Ile-190 and Pro-193; Gq numbering),
these findings attest to the notion that the number of required
amino acid switches for gain of FR inhibition likely correlates to
the extent of sequence divergence within the FR-binding site.
It follows that the molecular architecture of the interdomain
region confined by two flexible linkers offers unique opportu-
nities for specific pharmacological targeting of G protein
function with FR or YM mimics. However, to date, no single
analog prepared by chemical synthesis or isolated from natural
sources has shown activity on non-Gq/11/14 proteins (42, 46).
Conceivably, design of FR or YM analogs with altered G spec-
ificities may be more challenging than generally anticipated (1,
19, 33, 45). This may be due, at least in part, to the fact that FR
andYMare structurally complexmolecules that likely require a
network of residues for efficient engagement of their protein
targets (42). Herein, we used site-directed mutagenesis and
computational predictions to (i) define this network within
Gq and (ii) transplant it to G16, a Gq family member that is
naturally not regulated by the inhibitors. By substituting Gq
residues with their counterpart G16 sequences and vice versa,
we succeeded to completely swap pharmacology of oneG sub-
unit to that of the other for both depsipeptides. We noted that
potency contributions of individual amino acids were not sim-
ply additive but synergistic (Fig. S11), indicating that alteration
of one residue influences inhibitor activity at the others. This
interdependence suggests that multiple simultaneous interac-
tions are required for selective recognition of cognate depsi-
Figure 7. Unique hydrophobic interactions account for the divergent pharmacological profiles of FR and YM. YM (blue; A) and FR (orange; B) bound to
Gq plus homology models of G16 and G16FIVE highlighting (thin stick representation) key residues that engage in direct interactions with both inhibitors
or contribute indirectly via stabilizationof hydrogen-bondingor hydrophobic interactions are shown.Blue andorangemesh represents the vdWsurfaces of YM
andFR, respectively,whereasgray (carbon) andpurple/red/yellow (carbon/oxygen/sulfur) transparent surfaces illustrate the vdWsurfaceofGq-conserved and
G16-specific residues, respectively. Due to the ethyl and isopropyl versus methyl moieties, FR versus YM displays significantly larger vdW contact surface
complementarity to Pro-193 and the hydrophobic cluster (including positions Val-182/Ser-185 and Val-184/Met-187) in the binding site of all three G
proteins. These additional hydrophobic contacts partly compensate for theweakenedhydrophobic cluster and overall less hydrophobic nature of the binding
site in G16 (Ser-185, Met-187, Asn-193, and Cys-196), (i) making FR binding to, and inhibition of, Gq less vulnerable to mutations and (ii) explaining the FR
versus YM inhibition of WT G16 at high concentrations.
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peptide ligands. Accordingly, we expect multiple simultaneous
changes to be made to create FR or YMmimics that allow effi-
cient engagement of non-Gq targets.
Precision pharmacological targeting of heterotrimeric G
proteins in a G-specific manner still poses considerable chal-
lenges. Among all molecules interfering with G protein func-
tion, FR and YM are unique for their specific action on Gq
family proteins. Apparently, only nature has overcome the
major hurdles for development of G-specific inhibitors by
evolving FR and YM for optimal interaction with Gq, G11, and
G14. It will be intriguing to see whether depsipeptide mimics
with altered G selectivity profiles may become accessible via
semi- or total synthesis or via extension of nature’s chemistry
through combinatorial biosynthesis involving reconstitution
and manipulation of biosynthetic enzymes in heterologous
expression systems. Regardless, our here-designed depsipep-
tide-controlled G16 mutants provide (i) proof of principle
that FR-insensitive G subtypes may be targeted by similar
mechanisms and (ii) guidance for rational design of FR mimics
that recapitulate the modeled interactions between FR and
G16 proteins harboring engineered FR-binding sites.
Conclusions
Hydrophobic interactions have long been recognized as
major driving forces for macromolecular stability and complex
formation (62–64). FR and YM, two naturally occurring cyclic
depsipeptides, take advantage of such interactions to mediate
their specific inhibition of Gq. In turn, absence of the hydro-
phobic residues at equivalent positions in other G subunits is
consistent with the lack of FR/YM inhibition in these cases.We
have shown in our study that the hydrophobic functional
groups that discriminate FR from YM augment the contours of
the binding surface beyond thatwhich can be achievedwithYM
alone. We provided experimental evidence that hydrophobic
interactions explain the residual activity of FR onG16 and posit
their decisive importance to also account for the “superiority”
of FR over YM in the gain- and loss-of-function mutants.
Therefore, FR may be preferred over YM as privileged scaffold
in the search for specific and potent modulators targeting G16.
Experimental procedures
Materials and reagents
Cell culture materials were purchased from Invitrogen. FR
(previous commercial nameUBO-QIC) and FR-2 were isolated
and purified as described previously (33, 43). YM was obtained
fromWako Chemicals GmbH (Neuss, Germany). The synthe-
sis of YM-10 is detailed in Xiong et al. (45). Primary antibodies
to detect G16, the human influenza hemagglutinin (HA)
epitope tag (YPYDVPDYA), and -actin were from Santa Cruz
Biotechnology (Dallas, TX), Roche Applied Science, and Bio-
Legend (San Diego, CA), respectively. The horseradish peroxi-
dase (HRP)-conjugated secondary antibodies goat anti-mouse
IgG and goat anti-rabbit IgG were from Sigma-Aldrich and
Antibodies-onlineGmbH (Aachen, Germany), respectively. All
other reagents were purchased from Sigma-Aldrich if not
stated otherwise.
Cell culture
Generation of genetically engineered HEK293 cells using
CRISPR/Cas9 technology to knock out the subunits of Gq
and G11 (Gq/G11-null cells) is described elsewhere (33).
Genome-edited Gq/G11-null cells were used to establish
pooled clones stably expressing G16 WT and the mutant
isoforms G16E74DM187V N193I, G16S185VM187V N193I, and
G16FIVE that weremaintained under ZeocinTM selection (200
g/ml). Cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% (v/v) fetal calf serum, 100
units/ml penicillin, and 0.1 mg/ml streptomycin and kept in a
humidified atmosphere with 5% CO2 at 37 °C.
Site-directedmutagenesis and transfection
Mutations of the HA-tagged mouse Gq cDNA and the
humanG16 cDNA in pcDNA3.1() were generated using the
QuikChange method with specific primers (Table S3) as
detailed in the manufacturer’s protocol (Stratagene, La Jolla,
CA). Successful mutations were verified by DNA sequencing.
Subconfluent cell cultures were transiently transfectedwith the
respective expression plasmids using the polyethylenimine re-
agent (Polysciences, Warrington, PA) following the protocol
provided by the manufacturer.
Label-free DMR assay
DMRwas recorded as described previously (65, 66) using the
Epic System (Corning) together with the Cybi-SELMA semiau-
tomated electronic pipetting system (Analytik Jena AG, Jena,
Germany). In brief, 24 h after transfectionwith the correspond-
ing mutated G protein  subunits, HEK293 cells were counted
and seeded at a density of 17,000 cells/well on 384-well
fibronectin-coated biosensor plates. On the next day, cells were
washed twice with Hanks’ buffered salt solution containing 20
mM HEPES (HBSSHEPES) and incubated for 1 h at 37 °C in
the Epic reader. FR andYMwere added 1 h before themeasure-
ment inHBSSHEPES. The sensor platewas scanned to record
a baseline optical signature (no change in basal DMR), and after
agonist addition, DMR changes were monitored for 3,000 s at
37 °C.
Inositol monophosphate accumulation assay
HTRF-based IP1 accumulation assays (Cisbio, Codolet,
France) were performed according to the manufacturer’s
instructions. In brief, suspensions of 75,000 cells/well (G16-
expressing cell lines) or 15,000 cells/well (Gq transfectants)
were incubated for 20 min in the presence of LiCl prior to
administration of G protein inhibitors alone (Gq transfec-
tants) or combined treatment with G protein inhibitors and
CCh (G16 transfectants). G protein inhibitors FR and YM
were preincubated with cells for 1 h followed by 30 min of CCh
stimulation. Inositol monophosphate accumulation was subse-
quently measured using a Mithras LB940 multimode plate
reader (Berthold Technologies, Bad Wildbad, Germany).
Western blotting
48 h after transfection, cells were washed twice with PBS and
then lysed in ice-cold lysis buffer (25 mM Tris, pH 7.4, 150 mM
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NaCl, 1mMEDTA, 1%TritonX-100, 1% IGEPAL) at 4 °C. Lysates
were rotated for 20 min at 4 °C and centrifuged at 15,000  g at
4 °C for 10 min. To determine the protein concentration, the
PierceBCAProteinAssay (ThermoScientific,Waltham,MA)was
used following the manufacturer’s instructions. Lysates (15 g of
protein) were separated by 10% SDS-PAGE and transferred to
nitrocellulose membrane (HybondTM-C Extra from GE Health-
care) by electroblotting. Membranes were shortly washed with
PBS containing 0.1% Tween and then blocked with Roti-Block
(1; Carl Roth,Karlsruhe,Germany) for 1 h at room temperature.
Afterward, membranes were incubated overnight at 4 °C in Roti-
Block containing antibodies specific for G16 (1:1,000) or theHA
tag (1:1,000). After washing three times with PBS containing 0.1%
Tween, membranes were incubated for 1 h at room temperature
with a HRP-conjugated secondary goat anti-mouse IgG antibody
(1:10,000) in Roti-Block. For signal development of the immuno-
reactive proteins, theAmershamBiosciences ECLPrimeWestern
blotting detection reagent (GE Healthcare) was used. To normal-
ize for equal loading and protein transfer, membranes were
stripped, reprobed with an antibody against -actin (1:1,000–1:
2,500), and visualized after incubation with an HRP-conjugated
secondary goat anti-rabbit IgG antibody. Quantification of the
immunoreactive bands was carried out by densitometry using
ImageJ 1.52a (67) (National Institutes of Health).
Molecularmodeling and structural analysis
All structural analyses are based on theGq–YMcrystal struc-
ture (Protein Data Bank (PDB) code 3AH8). The G16–FR
homology model was constructed with Modeller 9.19 (Univer-
sity of California, San Francisco, CA) using the above-men-
tioned Gq–YM crystal structure as template. To adhere as
much as possible to the very closely related template structure,
the “very fast” keyword was utilized to output the initial model,
retaining the copied coordinates for all conserved residue posi-
tions. The YM inhibitor from theGq template was included in
the G16 model, and the propionyl plus isopropyl substituents
of FR were manually added to the inhibitor in PyMOL 2.0.6
(Schro¨dinger, NewYork, NY), ensuring a local minimum “stag-
gered” conformation with the least number of steric clashes.
Additionally, the mutations in the G16FIVE mutant were intro-
duced using the mutagenesis wizard in PyMOL, selecting the
side-chain rotamerwith the highest probability, resemblance to
the rotamer of the Gq–YM structure, and few steric clashes
with neighboring residues.
Data analysis
All data were analyzed using GraphPad Prism 8.0.0
(GraphPad Inc., La Jolla, CA). Quantification of DMR signals
was performed by calculation of the maximum responses. Data
points from concentration-response or inhibition curves of
individual functional experiments were fitted to the following
four-parameter logistic function.
Y  Bottom
Top Bottom
1 10logEC50 xslope
(Eq. 1)
Concentration-effect curves represented in figures were nor-
malized by setting each experimental maximal effect as 100%
response. All data are expressed as mean or S.E. of at least
three independent experiments performed in technical tripli-
cates. Concentration-inhibition curves that did not reach the
bottom plateau were constrained to plateau at zero, assuming
full inhibition.
Author contributions—D. M., D. E. G., H. B.-O., G. M. K., and E. K.
supervision; D. M., J. P., S. A., K. H., F. E., R. R., M. C., W. H., and
D. T. investigation; D. M., J. P., and K. H. visualization; K. H. and
E. K. writing-review and editing; R. R., M. C., W. H., H. Z., K. S.,
G. M. K., and A. I. resources; D. E. G. and E. K. funding acquisition;
J. G. and E. K. conceptualization; E. K. writing-original draft; E. K.
project administration.
References
1. Campbell, A. P., and Smrcka, A. V. (2018) Targeting G protein-coupled
receptor signalling by blocking G proteins. Nat. Rev. Drug Discov. 17,
789–803 CrossRef Medline
2. Gilman, A. G. (1987) G proteins: transducers of receptor-generated sig-
nals. Annu. Rev. Biochem. 56, 615–649 CrossRef Medline
3. Hepler, J. R., andGilman, A.G. (1992)G proteins.Trends Biochem. Sci. 17,
383–387 CrossRef Medline
4. Oldham, W. M., and Hamm, H. E. (2008) Heterotrimeric G protein acti-
vation by G-protein-coupled receptors.Nat. Rev. Mol. Cell Biol. 9, 60–71
CrossRef Medline
5. Milligan, G., and Kostenis, E. (2006) Heterotrimeric G-proteins: a short
history. Br. J. Pharmacol. 147, Suppl. 1, S46–S55 CrossRef Medline
6. Offermanns, S. (2003) G-proteins as transducers in transmembrane sig-
nalling. Prog. Biophys. Mol. Biol. 83, 101–130 CrossRef Medline
7. Simon, M. I., Strathmann, M. P., and Gautam, N. (1991) Diversity of G
proteins in signal transduction. Science 252, 802–808 CrossRef Medline
8. Lambert, N. A. (2008) Dissociation of heterotrimeric g proteins in cells.
Sci. Signal. 1, re5 CrossRef Medline
9. Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and
Sigler, P. B. (1996) The 2.0 Å crystal structure of a heterotrimeric G pro-
tein. Nature 379, 311–319 CrossRef Medline
10. Lokits, A. D., Indrischek, H., Meiler, J., Hamm, H. E., and Stadler, P. F.
(2018) Tracing the evolution of the heterotrimeric G protein  subunit in
Metazoa. BMC Evol. Biol. 18, 51 CrossRef Medline
11. Preininger, A. M., and Hamm, H. E. (2004) G protein signaling: insights
from new structures. Sci. STKE 2004, re3 CrossRef Medline
12. Sprang, S. R. (1997) G protein mechanisms: insights from structural anal-
ysis. Annu. Rev. Biochem. 66, 639–678 CrossRef Medline
13. Johnston, C. A., and Siderovski, D. P. (2007) Receptor-mediated activation
of heterotrimeric G-proteins: current structural insights.Mol. Pharmacol.
72, 219–230 CrossRef Medline
14. Jones, J. C., Duffy, J. W., Machius, M., Temple, B. R., Dohlman, H. G., and
Jones, A. M. (2011) The crystal structure of a self-activating G protein 
subunit reveals its distinct mechanism of signal initiation. Sci. Signal. 4,
ra8 CrossRef Medline
15. Jones, J. C., Jones, A. M., Temple, B. R., and Dohlman, H. G. (2012) Dif-
ferences in intradomain and interdomain motion confer distinct activa-
tion properties to structurally similar G proteins. Proc. Natl. Acad. Sci.
U.S.A. 109, 7275–7279 CrossRef Medline
16. Preininger, A. M., Meiler, J., and Hamm, H. E. (2013) Conformational
flexibility and structural dynamics in GPCR-mediated G protein activa-
tion: a perspective. J. Mol. Biol. 425, 2288–2298 CrossRef Medline
17. Hamm, H. E., and Gilchrist, A. (1996) Heterotrimeric G proteins. Curr.
Opin. Cell Biol. 8, 189–196 CrossRef Medline
18. Wall, M. A., Coleman, D. E., Lee, E., In˜iguez-Lluhi, J. A., Posner, B. A.,
Gilman, A. G., and Sprang, S. R. (1995) The structure of the G protein
heterotrimer Gi112. Cell 83, 1047–1058 CrossRef Medline
19. Nishimura, A., Kitano, K., Takasaki, J., Taniguchi, M., Mizuno, N., Tago,
K., Hakoshima, T., and Itoh, H. (2010) Structural basis for the specific
Transfer of FR900359 and YM-254890 sites fromGq to G16
5756 J. Biol. Chem. (2019) 294(15) 5747–5758
 at Copenhagen U
niversity Library on Septem
ber 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
inhibition of heterotrimeric Gq protein by a small molecule. Proc. Natl.
Acad. Sci. U.S.A. 107, 13666–13671 CrossRef Medline
20. Noel, J. P., Hamm,H. E., and Sigler, P. B. (1993) The 2.2 Å crystal structure
of transducin- complexed with GTPS.Nature 366, 654–663 CrossRef
Medline
21. Dror, R. O., Mildorf, T. J., Hilger, D., Manglik, A., Borhani, D. W., Arlow,
D.H., Philippsen, A., Villanueva, N., Yang, Z., Lerch,M. T., Hubbell,W. L.,
Kobilka, B. K., Sunahara, R. K., and Shaw, D. E. (2015) SIGNAL TRANS-
DUCTION. Structural basis for nucleotide exchange in heterotrimeric G
proteins. Science 348, 1361–1365 CrossRef Medline
22. Lutz, S., Baltus, D., Jakobs, K. H., and Niroomand, F. (2002) Spontaneous
release of GDP from Gi proteins and inhibition of adenylyl cyclase in
cardiac sarcolemmal membranes. Naunyn Schmiedebergs Arch. Pharma-
col. 365, 50–55 CrossRef Medline
23. Maziarz, M., Leyme, A., Marivin, A., Luebbers, A., Patel, P. P., Chen, Z.,
Sprang, S. R., and Garcia-Marcos, M. (2018) Atypical activation of Gq by
the oncogenic mutation Q209P. J. Biol. Chem. 293, 19586–19599
CrossRef Medline
24. Siekhaus, D. E., and Drubin, D. G. (2003) Spontaneous receptor-indepen-
dent heterotrimeric G-protein signalling in an RGSmutant.Nat. Cell Biol.
5, 231–235 CrossRef Medline
25. Chung, K. Y., Rasmussen, S. G., Liu, T., Li, S., DeVree, B. T., Chae, P. S.,
Calinski, D., Kobilka, B. K., Woods, V. L., Jr., and Sunahara, R. K. (2011)
Conformational changes in theGproteinGs induced by the2 adrenergic
receptor. Nature 477, 611–615 CrossRef Medline
26. Goricanec,D., Stehle, R., Egloff, P., Grigoriu, S., Plu¨ckthun,A.,Wagner,G.,
and Hagn, F. (2016) Conformational dynamics of a G-protein  subunit is
tightly regulated by nucleotide binding. Proc. Natl. Acad. Sci. U.S.A. 113,
E3629–E3638 CrossRef Medline
27. Mahoney, J. P., and Sunahara, R. K. (2016) Mechanistic insights into
GPCR-G protein interactions. Curr. Opin. Struct. Biol. 41, 247–254
CrossRef Medline
28. Hollinger, S., and Hepler, J. R. (2002) Cellular regulation of RGS proteins:
modulators and integrators of G protein signaling. Pharmacol. Rev. 54,
527–559 CrossRef Medline
29. Gulati, S., Jin, H., Masuho, I., Orban, T., Cai, Y., Pardon, E., Martemyanov,
K. A., Kiser, P. D., Stewart, P. L., Ford, C. P., Steyaert, J., and Palczewski, K.
(2018) Targeting G protein-coupled receptor signaling at the G protein
level with a selective nanobody inhibitor.Nat. Commun. 9, 1996 CrossRef
Medline
30. Bonacci, T. M., Mathews, J. L., Yuan, C., Lehmann, D. M., Malik, S., Wu,
D., Font, J. L., Bidlack, J.M., and Smrcka, A. V. (2006)Differential targeting
of G-subunit signaling with small molecules. Science 312, 443–446
CrossRef Medline
31. Katada, T., and Ui, M. (1982) Direct modification of the membrane ad-
enylate cyclase system by islet-activating protein due to ADP-ribosylation
of a membrane protein. Proc. Natl. Acad. Sci. U.S.A. 79, 3129–3133
CrossRef Medline
32. Cassel, D., and Pfeuffer, T. (1978) Mechanism of cholera toxin action:
covalent modification of the guanyl nucleotide-binding protein of the ad-
enylate cyclase system. Proc. Natl. Acad. Sci. U.S.A. 75, 2669–2673
CrossRef Medline
33. Schrage, R., Schmitz, A. L., Gaffal, E., Annala, S., Kehraus, S., Wenzel, D.,
Bu¨llesbach, K. M., Bald, T., Inoue, A., Shinjo, Y., Galandrin, S., Shridhar,
N., Hesse,M., Grundmann,M.,Merten, N., et al. (2015) The experimental
power of FR900359 to studyGq-regulated biological processes.Nat. Com-
mun. 6, 10156 CrossRef Medline
34. Bolognini, D., Moss, C. E., Nilsson, K., Petersson, A. U., Donnelly, I., Ser-
geev, E., Ko¨nig, G. M., Kostenis, E., Kurowska-Stolarska, M., Miller, A.,
Dekker, N., Tobin, A. B., andMilligan, G. (2016) A novel allosteric activa-
tor of free fatty acid 2 receptor displays unique Gi-functional bias. J. Biol.
Chem. 291, 18915–18931 CrossRef Medline
35. Inamdar, V., Patel, A., Manne, B. K., Dangelmaier, C., and Kunapuli, S. P.
(2015) Characterization of UBO-QIC as a Gq inhibitor in platelets.
Platelets 26, 771–778 CrossRef Medline
36. Klepac, K., Kilic´, A., Gnad, T., Brown, L.M., Herrmann, B.,Wilderman, A.,
Balkow, A., Glo¨de, A., Simon, K., Lidell, M. E., Betz, M. J., Enerba¨ck, S.,
Wess, J., Freichel, M., Blu¨her, M., et al. (2016) The Gq signalling pathway
inhibits brown and beige adipose tissue.Nat. Commun. 7, 10895 CrossRef
Medline
37. Liao, Y., Lu, B.,Ma,Q.,Wu,G., Lai, X., Zang, J., Shi, Y., Liu, D., Han, F., and
Zhou, N. (2016) Human neuropeptide S receptor is activated via a Gq
protein-biased signaling cascade by a human neuropeptide S analog lack-
ing the C-terminal 10 residues. J. Biol. Chem. 291, 7505–7516 CrossRef
Medline
38. Matthey, M., Roberts, R., Seidinger, A., Simon, A., Schro¨der, R., Kuschak,
M., Annala, S., Ko¨nig, G. M., Mu¨ller, C. E., Hall, I. P., Kostenis, E., Fleis-
chmann, B. K., andWenzel, D. (2017) Targeted inhibition of Gq signaling
induces airway relaxation in mouse models of asthma. Sci. Transl. Med. 9,
eaag2288 CrossRef Medline
39. Zaima, K., Deguchi, J., Matsuno, Y., Kaneda, T., Hirasawa, Y., andMorita,
H. (2013) Vasorelaxant effect of FR900359 from Ardisia crenata on rat
aortic artery. J. Nat. Med. 67, 196–201 CrossRef Medline
40. Cru¨semann,M., Reher, R., Schamari, I., Brachmann, A. O., Ohbayashi, T.,
Kuschak, M., Malfacini, D., Seidinger, A., Pinto-Carbo´, M., Richarz, R.,
Reuter, T., Kehraus, S., Hallab, A., Attwood,M., Schio¨th,H. B., et al. (2018)
Heterologous expression, biosynthetic studies, and ecological function of
the selectiveGq-signaling inhibitor FR900359.Angew. Chem. Int. Ed. Engl.
57, 836–840 CrossRef Medline
41. Kaur, H., Harris, P. W., Little, P. J., and Brimble, M. A. (2015) Total syn-
thesis of the cyclic depsipeptide YM-280193, a platelet aggregation inhib-
itor. Org. Lett. 17, 492–495 CrossRef Medline
42. Reher, R., Ku¨hl, T., Annala, S., Benkel, T., Kaufmann, D., Nubbemeyer, B.,
Odhiambo, J. P., Heimer, P., Ba¨uml, C. A., Kehraus, S., Cru¨semann, M.,
Kostenis, E., Tietze, D., Ko¨nig, G. M., and Imhof, D. (2018) Deciphering
specificity determinants for FR900359-derived Gq inhibitors based on
computational and structure-activity studies. ChemMedChem 13,
1634–1643 CrossRef Medline
43. Reher, R., Kuschak, M., Heycke, N., Annala, S., Kehraus, S., Dai, H. F.,
Mu¨ller, C. E., Kostenis, E., Ko¨nig, G. M., and Cru¨semann, M. (2018) Ap-
plying molecular networking for the detection of natural sources and an-
alogues of the selective Gq protein inhibitor FR900359. J. Nat. Prod. 81,
1628–1635 CrossRef Medline
44. Rensing, D. T., Uppal, S., Blumer, K. J., and Moeller, K. D. (2015) Toward
the selective inhibition of G proteins: total synthesis of a simplified YM-
254890 analog. Org. Lett. 17, 2270–2273 CrossRef Medline
45. Xiong, X. F., Zhang, H., Underwood, C. R., Harpsøe, K., Gardella, T. J.,
Wo¨ldike, M. F., Mannstadt, M., Gloriam, D. E., Bra¨uner-Osborne, H., and
Strømgaard, K. (2016) Total synthesis and structure-activity relationship
studies of a series of selective G protein inhibitors. Nat. Chem. 8,
1035–1041 CrossRef Medline
46. Zhang, H., Nielsen, A. L., Boesgaard, M. W., Harpsøe, K., Daly, N. L.,
Xiong, X. F., Underwood, C. R., Haugaard-Kedstro¨m, L. M., Bra¨uner-
Osborne, H., Gloriam, D. E., and Strømgaard, K. (2018) Structure-activity
relationship and conformational studies of the natural product cyclic dep-
sipeptides YM-254890 and FR900359. Eur. J. Med. Chem. 156, 847–860
CrossRef Medline
47. Zhang, H., Xiong, X. F., Boesgaard, M. W., Underwood, C. R., Bra¨uner-
Osborne, H., and Strømgaard, K. (2017) Structure-activity relationship
studies of the cyclic depsipeptide natural product YM-254890, targeting
the Gq protein. ChemMedChem 12, 830–834 CrossRef Medline
48. Taniguchi, M., Suzumura, K., Nagai, K., Kawasaki, T., Takasaki, J., Sekigu-
chi, M., Moritani, Y., Saito, T., Hayashi, K., Fujita, S., Tsukamoto, S., and
Suzuki, K. (2004) YM-254890 analogues, novel cyclic depsipeptides with
Gq/11 inhibitory activity from Chromobacterium sp. QS3666. Bioorg.
Med. Chem. 12, 3125–3133 CrossRef Medline
49. Li, B., Tunc-Ozdemir, M., Urano, D., Jia, H., Werth, E. G., Mowrey, D. D.,
Hicks, L. M., Dokholyan, N. V., Torres, M. P., and Jones, A. M. (2018)
Tyrosine phosphorylation switching of a G protein. J. Biol. Chem. 293,
4752–4766 CrossRef Medline
50. Skinner, J. J.,Wang, S., Lee, J., Ong, C., Sommese, R., Sivaramakrishnan, S.,
Koelmel, W., Hirschbeck, M., Schindelin, H., Kisker, C., Lorenz, K., Sos-
nick, T. R., and Rosner, M. R. (2017) Conserved salt-bridge competition
triggered by phosphorylation regulates the protein interactome. Proc.
Natl. Acad. Sci. U.S.A. 114, 13453–13458 CrossRef Medline
Transfer of FR900359 and YM-254890 sites fromGq to G16
J. Biol. Chem. (2019) 294(15) 5747–5758 5757
 at Copenhagen U
niversity Library on Septem
ber 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
51. Walther, T. H., and Ulrich, A. S. (2014) Transmembrane helix assembly
and the role of salt bridges. Curr. Opin. Struct. Biol. 27, 63–68 CrossRef
Medline
52. Bynagari, Y. S., Nagy, B., Jr., Tuluc, F., Bhavaraju, K., Kim, S., Vijayan, K. V.,
and Kunapuli, S. P. (2009) Mechanism of activation and functional role of
protein kinase C	 in human platelets. J. Biol. Chem. 284, 13413–13421
CrossRef Medline
53. Canals,M., Jenkins, L., Kellett, E., andMilligan, G. (2006) Up-regulation of
the angiotensin II type 1 receptor by the MAS proto-oncogene is due to
constitutive activation of Gq/G11 by MAS. J. Biol. Chem. 281,
16757–16767 CrossRef Medline
54. Goh, F. G., Ng, P. Y., Nilsson, M., Kanke, T., and Plevin, R. (2009) Dual
effect of the novel peptide antagonist K-14585 on proteinase-activated
receptor-2-mediated signalling. Br. J. Pharmacol. 158, 1695–1704
CrossRef Medline
55. Higa-Nakamine, S., Maeda, N., Toku, S., and Yamamoto, H. (2015) In-
volvement of protein kinase D1 in signal transduction from the protein
kinase C pathway to the tyrosine kinase pathway in response to gonado-
tropin-releasing hormone. J. Biol. Chem. 290, 25974–25985 CrossRef
Medline
56. Hisaoka-Nakashima, K., Miyano, K., Matsumoto, C., Kajitani, N., Abe, H.,
Okada-Tsuchioka,M., Yokoyama,A., Uezono, Y.,Morioka,N.,Nakata, Y.,
and Takebayashi, M. (2015) Tricyclic antidepressant amitriptyline-in-
duced glial cell line-derived neurotrophic factor production involves per-
tussis toxin-sensitive Gi/o activation in astroglial cells. J. Biol. Chem. 290,
13678–13691 CrossRef Medline
57. Orth, J. H., Lang, S., Taniguchi, M., and Aktories, K. (2005) Pasteurella
multocida toxin-induced activation of RhoA is mediated via two families
of G proteins, Gq and G12/13. J. Biol. Chem. 280, 36701–36707
CrossRef Medline
58. Takasaki, J., Saito, T., Taniguchi, M., Kawasaki, T., Moritani, Y., Hayashi,
K., and Kobori,M. (2004) A novel Gq/11-selective inhibitor. J. Biol. Chem.
279, 47438–47445 CrossRef Medline
59. Yasui, F., Miyazu, M., Yoshida, A., Naruse, K., and Takai, A. (2008) Exam-
ination of signalling pathways involved in muscarinic responses in bovine
ciliary muscle using YM-254890, an inhibitor of the Gq/11 protein. Br. J.
Pharmacol. 154, 890–900 CrossRef Medline
60. Kimple, R. J., Kimple, M. E., Betts, L., Sondek, J., and Siderovski, D. P.
(2002) Structural determinants for GoLoco-induced inhibition of nucle-
otide release by G subunits. Nature 416, 878–881 CrossRef Medline
61. Onken, M. D., Makepeace, C. M., Kaltenbronn, K. M., Kanai, S. M., Todd,
T. D., Wang, S., Broekelmann, T. J., Rao, P. K., Cooper, J. A., and Blumer,
K. J. (2018) Targeting nucleotide exchange to inhibit constitutively active
G protein  subunits in cancer cells. Sci. Signal. 11, eaao6852 CrossRef
Medline
62. Clackson, T., and Wells, J. A. (1995) A hot spot of binding energy in a
hormone-receptor interface. Science 267, 383–386 CrossRef Medline
63. Eriksson, A. E., Baase, W. A., Zhang, X. J., Heinz, D. W., Blaber, M., Bald-
win, E. P., and Matthews, B. W. (1992) Response of a protein structure to
cavity-creating mutations and its relation to the hydrophobic effect. Sci-
ence 255, 178–183 CrossRef Medline
64. Kellis, J. T., Jr, Nyberg, K., Sali, D., and Fersht, A. R. (1988) Contribution of
hydrophobic interactions to protein stability. Nature 333, 784–786
CrossRef Medline
65. Schro¨der, R., Schmidt, J., Bla¨ttermann, S., Peters, L., Janssen, N., Grund-
mann, M., Seemann, W., Kaufel, D., Merten, N., Drewke, C., Gomeza, J.,
Milligan, G., Mohr, K., and Kostenis, E. (2011) Applying label-free dy-
namic mass redistribution technology to frame signaling of G protein-
coupled receptors noninvasively in living cells.Nat. Protoc. 6, 1748–1760
CrossRef Medline
66. Schro¨der, R., Janssen, N., Schmidt, J., Kebig, A., Merten, N., Hennen, S.,
Mu¨ller, A., Bla¨ttermann, S., Mohr-Andra¨, M., Zahn, S., Wenzel, J., Smith,
N. J., Gomeza, J., Drewke, C., Milligan, G., et al. (2010) Deconvolution of
complex G protein-coupled receptor signaling in live cells using dynamic
mass redistribution measurements. Nat. Biotechnol. 28, 943–949
CrossRef Medline
67. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to
ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 CrossRef
Medline
Transfer of FR900359 and YM-254890 sites fromGq to G16
5758 J. Biol. Chem. (2019) 294(15) 5747–5758
 at Copenhagen U
niversity Library on Septem
ber 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Gomeza and Evi Kostenis
Hans Bräuner-Osborne, Kristian Strømgaard, Gabriele M. König, Asuka Inoue, Jesus 
Gloriam,Reher, Max Crüsemann, Wiebke Hanke, Hang Zhang, Daniel Tietze, David E. 
Davide Malfacini, Julian Patt, Suvi Annala, Kasper Harpsøe, Funda Eryilmaz, Raphael
sensitivity
 subunit with artificial inhibitorαRational design of a heterotrimeric G protein 
doi: 10.1074/jbc.RA118.007250 originally published online February 11, 2019
2019, 294:5747-5758.J. Biol. Chem. 
  
 10.1074/jbc.RA118.007250Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/294/15/5747.full.html#ref-list-1
This article cites 67 references, 28 of which can be accessed free at
 at Copenhagen U
niversity Library on Septem
ber 17, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
